NPPA fixed retail price of 23 formulations: June 2023

Last Updated on January 6, 2024 by The Health Master

Download NPPA notification No. S.O. S.O. 2539(E) dt 08-06-2023, the link is given below: The National Pharmaceutical Pricing Authority (NPPA) has fixed the retail prices of 23 formulations under the Drugs (Prices Control) Order, 2013, vide S.O. 2539(E) dt 08-06-2023 based on the decision of the 113th Authority meeting dated 26-05-2023.

This price fixation followed the decision of the 113th Authority meeting on May 26, 2023

The notification states as under:

In exercise of the powers conferred by paragraphs 5, 11 and 15 of the Drugs (Prices Control) Order, 2013, read with S.O. 1394(E) dated the 30th May, 2013 and S. O. 5249(E) dated 11th November, 2022 issued by the Government of India in the Ministry of Chemicals and Fertilizers, the National Pharmaceutical Pricing Authority (hereinafter referred as NPPA), hereby fixes, the price as specified in column (6) of the table herein below as the retail price, exclusive of Goods and Services Tax, if any, in relation to the formulation specified in the corresponding entry in column (2) of the said Table with the strength, unit and name of manufacturer & marketing company, as specified in the corresponding entries in columns (3), (4) and (5) thereof;

Table is given below the article

Note:
(a) The manufacturer of the above-mentioned formulations, i.e., the “new drug” under paragraph 2(1)(u) of the DPCO, 2013 shall fix the retail price as specified in column (6) of the table hereinabove.

(b) The manufacturer may add Goods and Services Tax only if they have paid actually or it is payable to the Government on the retail price mentioned in column (6) of the above said table.

(c) The retail price for a pack of the aforesaid formulation shall be arrived at by the concerned manufacturer in accordance with the retail price specified in column (6) of the above table as per provisions contained in paragraph 11 of the DPCO, 2013.

The manufacturer shall issue a price list in Form–V from date of Notification as per paragraph 24 of the DPCO, 2013 to NPPA through IPDMS and submit a copy to State Drug Controller and dealers.

(d) As per para 24(4) of DPCO 2013, every retailer and dealer shall display price list and the supplementary price list, if any, as furnished by the manufacturer, on a conspicuous part of the premises where he carries on business in a manner so as to be easily accessible to any person wishing to consult the same.

(e) The above mentioned retail price is applicable only to the individual manufacturer / marketer as mentioned above i.e.. who have applied for the same by submitting Form-I for price fixation / revision as stipulated under DPCO, 2013 and subject to fulfilment of all the applicable statutory requirements as laid down by the Govt. under relevant statutes/ rules,
including manufacturing license permission from the competent authority, i.e., the central or state licensing authority, as may be applicable, by the concerned manufacturer/marketing company.

(f) In case the retail price of any of the aforesaid formulations is not complied with, as per the instant price notification and notes specified hereinabove, then the concerned manufacturer / marketing company shall be liable to deposit the overcharged amount along with the interest thereon under the provisions of the DPCO, 2013 read with the Essential Commodities Act, 1955.

(g) Consequent to the fixation of retail price of such formulation as specified in column (2) of the above table with the strength and name of Manufacturer & Marketing Companies specified in the corresponding entries in Column (3) & (5) thereof, the price order(s) fixing the retail price of the formulation with specified strength for that Manufacturer & Marketing
Companies as specified in corresponding entries in Columns (2), (3), and (5) thereof, if any, issued prior to this notification, stand superseded.

Table

Sl. No .	Name of the Formulation / Brand Name	Strength	Unit	Manufacturer & Marketing Company	Retail Price (Rs.)
(1)	(2)	(3)	(4)	(5)	(6)
1	Trypsin, Bromelain, Rutoside Trihydrate and Diclofenac Sodium Tablets	Each enteric coated tablet contains: Trypsin BP 48mg Bromelain 90mg Rutoside Trihydrate BP 100mg Diclofenac Sodium IP 50mg	1 Tablet	M/s Synokem Pharmaceuticals Limited / M/s Troikaa Pharmaceuticals Ltd.	20.51
2	Gliclazide ER and Metformin Hydrochloride (ER) Tablets	Each uncoated bilayer tablet contains: Gliclazide IP 60mg (as extended-release form) Metformin Hydrochloride IP 1000mg (as extended- release form)	1 Tablet	M/s Ravenbhel Healthcare Pvt. Ltd. / M/s Mankind Pharma Ltd.	10.03
3	Telmisartan, Chlorthalidone & Cilnidipine tablets	Each film coated tablet contains: Telmisartan IP 40mg Chlorthalidone IP 6.25mg Cilnidipine IP 10mg	1 Tablet	M/s Mascot Health Series Pvt. Ltd. / M/s Eris Lifesciences Limited	13.17
4	Amoxycillin and Potassium Clavulanate Oral Suspension IP	Each 5ml of constituted suspension contains: Amoxycillin Trihydrate IP eq. to Amoxycillin 400mg Potassium Clavulanate Diluted IP eq. to Clavulanic Acid 57mg	1 ml	M/s Alps Communication Pvt. Ltd. / M/s Mankind Prime Labs Pvt. Ltd.	4.05
5	Aceclofenac + Paracetamol + Serratiopeptidas e Tablet	Each film coated tablet contains: Aceclofenac IP 100mg, Paracetamol IP 325mg Serratiopeptidase IP 10mg (As enteric coated granules eq. to 20000 enzyme actuvity unity of serratiopeptidase)	1 Tablet	M/s Akums Drugs & Pharmaceuticals Ltd. /M/s German Remedies Pharmaceuticals Pvt. Ltd.	5.23
6	Aceclofenac + Paracetamol + Serratiopeptidas e Tablet	Each film coated tablet contains: Aceclofenac IP 100mg, Paracetamol IP 325mg Serratiopeptidase IP 15mg (As enteric coated granules eq. to 30000 enzyme actuvity unity of serratiopeptidase)	1 Tablet	M/s Akums Drugs & Pharmaceuticals Ltd. /M/s German Remedies Pharmaceuticals Pvt. Ltd.	8.09
7	Ofloxacin and Metronidazole suspension	Each 5ml contains: Ofloxacin IP 50mg Metronidazole Benzoate IP eq. to Metronidazole 100mg	1 ml	M/s Skymap Pharmaceuticals Pvt. Ltd./ M/s German Remedies Pharmaceuticals Pvt. Ltd.	0.72

8	Diclofenac Diethylamine, Methyl Salicylate, Menthol & Virgin Linseed Oil Topical Spray	Composition: Diclofenac Diethylamine IP 1.16%w/w eq. to Diclofenac Sodium IP 1% Virgin Linseed Oil BP 3% w/w Methyl Salicylate IP 10% w/w Menthol IP 5%w/w	1 Gm	M/s Pontika Aerotech Limited / M/s Abbott Healthcare Pvt. Ltd.	2.69
9	Alpha Lipoic Acid, Methylcobalami n, Vitamin B6, Folic Acid, Benfotaimine, Biotin & Chromium Picolinate Capsule	Each hard gelatin capsule contains: Alpha Lipoic Acid USP 100mg Methylcobalamin IP 1500mcg Vitamin B6 IP 3mg Folic Acid IP 1.5mg Benfotaimine 50mg Biotin USP 5mg Chromium Picolinate USP eq. to Chromium 200mcg	1 Capsule	M/s Theon Pharmaceuticals Ltd. / M/s German Remedies Pharmaceuticals Pvt. Ltd.	13.57
10	Lidocaine & Prilocaine Spray	Each actuation spray contains:Lidocaine 7.5mgPrilocaine 2.5mg	1 Gm	M/s Pontika Aerotech / M/s Mankind Pharma Ltd.	34.52
11	Sodium Alginate, Sodium Bicarbonate & Calcium Carbonate Oral Suspension	Each 5ml contains: Sodium Alginate IP 250mg Sodium Bicarbonate IP 133.5mg Calcium Carbonate IP 80mg	1 ml	M/s Akums Drugs & Pharmaceuticals Ltd. / M/s Mankind Pharma Ltd.	0.88
12	Atorvastatin, Clopidogrel & Aspirin Capsule	Each hard gelatin capsule contains: Atorvastatin Calcium IP eq. to Atorvastatin 40mg (As white coloured pellets) Clopidogrel Bisulphate IP eq. to Clopidogrel 75mg (As two reddish brown coloured film coated tablets, each containing 37.5mg clopidogrel tablets IP) Aspirin IP 75mg (As enteric coated white-coloured pellets)	1 Capsule	M/s Windlas Biotech Limited / M/s Zydus Healthcare Limited	13.22
13	Telmisartan and Bisoprolol Fumarate Tablets	Each film coated tablet contains: Telmisartan IP 40mg Bisoprolol Fumarate IP 2.5mg	1 Tablet	M/s Ravenbhel Healthcare Pvt. Ltd. / M/s Emcure Pharmaceuticals Limited	10.97
14	Telmisartan and Bisoprolol Fumarate Tablets	Each film coated tablet contains: Telmisartan IP 40mg Bisoprolol Fumarate IP 5mg	1 Tablet	M/s Ravenbhel Healthcare Pvt. Ltd. / M/s Emcure Pharmaceuticals Limited	12.62
15	Telmisartan and Bisoprolol Fumarate Tablets	Each film coated tablet contains: Telmisartan IP 40mg Bisoprolol Fumarate IP 2.5mg	1 Tablet	M/s Ravenbhel Healthcare Pvt. Ltd. / M/s Alembic Pharmaceuticals Ltd.	9.82

16	Telmisartan and Bisoprolol Fumarate Tablets	Each film coated tablet contains: Telmisartan IP 40mg Bisoprolol Fumarate IP 5mg	1 Tablet	M/s Ravenbhel Healthcare Pvt. Ltd. / M/s Alembic Pharmaceuticals Ltd.	11.60
17	Azelnidipine and Telmisartan Tablet	Each uncoated bilayered tablet contains: Azelnidipine IP 16mg Telmisartan IP 40mg.	1 Tablet	M/s Mascot Health Series Pvt. Ltd. / M/s Torrent Pharmaceuticals Limited	17.96
18	Azelnidipine and Telmisartan Tablet	Each uncoated bilayered tablet contains: Azelnidipine IP 16mg Telmisartan IP 40mg.	1 Tablet	M/s Mascot Health Series Pvt. Ltd. / M/s Glenmark Pharmaceuticals Limited	17.82
19	Paraccetamol and Caffeine Tablets IP	Each uncoated tablet contains: Paracetamol IP 500mg Caffeine IP 50mg	1 Tablet	M/s Troikaa Pharmaceuticals Limited	1.77
20	Atorvastatin and Bempedoic Acid Tablets	Each film coated tablet contains: Bempedoic Acid 180mg Atorvastatin Calcium IP eq. to Atorvastatin 80mg	1 Tablet	M/s Exemed Pharmaceuticals / M/s Eris Lifesciences Limited	52.97
21	Ofloxacin & Dexamethasone Sodium Phosphate Eye/Ear Drops	Composition: Ofloxacin IP 0.3%w/v Dexamethasone Sodium Phosphate IP 0.1% w/v Sterile aqueous Vehicle q.s.	1 ml	M/s Skymap Healthcare Pvt. Ltd. /M/s Healing Pharma India Pvt. Ltd.	5.80
22	Bilastine and Montelukast Oral Suspenssion	Each 5ml suspension contains: Bilastine 10mg Montelukast Sodium IP eq. to Monelukast 4mg	1 ml	M/s Ravenbhel Healthcare Pvt. Ltd. / M/s Aristo Pharmaceuticals Pvt. Ltd.	1.71
23	Formoterol Fumarate and Budesonide Respirator Suspension	Each 2ml pulmule contains: Formoterol Fumarate Dihydrate IP eq. to Foroterol Fumarate 20mcg Budesonide IP 1mg	Per Pulmule of 2 ml	M/s Alkem Laboratories Limited	56.20

For informative videos on the news regarding Pharma / Medical Devices / Cosmetics / Homoeopathy etc., click on the below YouTube icon:

For informative videos by The Health Master, click on the below YouTube icon:

• Fire explosion at Aurore Pharmaceuticals
  November 21, 2024
• Drug recall: Cipla recalls over 1.8k boxes of this drug
  November 21, 2024
• USFDA issued Form 483 with 7 observations to Dr Reddy’s
  November 20, 2024
• NPPA Revises Ceiling Prices of these Key Drugs
  November 20, 2024
• Approval of Anti Cancer drug Nivolumab for new Indication
  November 19, 2024
• Trump 2.0 Agenda: A Boon for Indian Pharma Industry?
  November 19, 2024

For informative videos on Medical Store / Pharmacy, click on the below YouTube icon:

For informative videos on the news regarding Pharma / Medical Devices / Cosmetics / Homoeopathy etc., click on the below YouTube icon:

For informative videos on consumer awareness, click on the below YouTube icon: